Henry J. Fuchs
2014
In 2014, Henry J. Fuchs earned a total compensation of $3.6M as President, Worldwide R&D at BioMarin Pharmaceutical, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $250,113 |
|---|---|
| Option Awards | $1,794,048 |
| Salary | $528,235 |
| Stock Awards | $984,360 |
| Other | $18,338 |
| Total | $3,575,094 |
Fuchs received $1.8M in option awards, accounting for 50% of the total pay in 2014.
Fuchs also received $250.1K in non-equity incentive plan, $528.2K in salary, $984.4K in stock awards and $18.3K in other compensation.
Rankings
In 2014, Henry J. Fuchs' compensation ranked 2,459th out of 13,032 executives tracked by ExecPay. In other words, Fuchs earned more than 81.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,459 out of 13,032 | 81st |
Division Manufacturing | 868 out of 4,966 | 83rd |
Major group Chemicals And Allied Products | 267 out of 1,686 | 84th |
Industry group Drugs | 207 out of 1,365 | 85th |
Industry Pharmaceutical Preparations | 169 out of 1,043 | 84th |
Source: SEC filing on April 25, 2017.
Fuchs' colleagues
We found four more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2014.
2014
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2014
Daniel Spiegelman
BioMarin Pharmaceutical
Chief Financial Officer
2014
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
2014
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
News
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
April 12, 2022
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2020 pay slips 2% to $18M
April 13, 2021
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
April 14, 2020
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
April 23, 2019